Janux Therapeutics Inc (NASDAQ:JANX) shares, rose in value on Friday, March 07, with the stock price down by -0.36% to the previous day’s close as strong demand from buyers drove the stock to $30.64.
Actively observing the price movement in the last trading, the stock closed the session at $30.75. Referring to stock’s 52-week performance, its high was $71.71, and the low was $29.63. On the whole, JANX has fluctuated by -31.38% over the past month.
With the market capitalization of Janux Therapeutics Inc currently standing at about $1.81 billion, investors are eagerly awaiting this quarter’s results, scheduled for in April.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 400k.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that JANX’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the price of JANX currently trading nearly -11.15% and -27.20% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 31.16, while the 7-day volatility ratio is showing 5.75% which for the 30-day chart, stands at 6.00%. Furthermore, Janux Therapeutics Inc (JANX)’s beta value is 3.23, and its average true range (ATR) is 2.26.
A comparison of Janux Therapeutics Inc (JANX) with its peers suggests the former has fared considerably weaker in the market. JANX showed an intraday change of -0.36% in last session, and over the past year, it shrunk by -29.14%%.
Data on historical trading for Janux Therapeutics Inc (NASDAQ:JANX) indicates that the trading volumes over the past 3 months, they’ve averaged 991.59K. According to company’s latest data on outstanding shares, there are 59.06 million shares outstanding.
Nearly 16.79% of Janux Therapeutics Inc’s shares belong to company insiders and institutional investors own 106.49% of the company’s shares. The stock has fallen by -42.77% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the JANX stock heading into the next quarter.
